REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.91
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.18 (22.18%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.91
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Arena soars on takeover; Accrol supply chain hit

Wed, 20th Oct 2021 10:56

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Arena Events Group PLC, up 43% at 20.30 pence, 12-month range 4.01p-21p. The firm - which services major events, supplying things such as temporary physical structures and seating - agrees to be taken over by Theta Bidco Ltd in deal worth enterprise value of GBP95.1 million. The suitor - owned by joint offerors IHC Industrial Holding LLC and Tasheel Holding Group LLC - will pay 21p per Arena share, being a 48% premium to Tuesday's closing price. It values Arena's entire issued share capital at GBP71.0 million. "IHC and Tasheel are both diversified holding companies, formed as part of initiatives to diversify and grow non-oil business sectors in the United Arab Emirates and Saudi Arabia respectively. Arena fits well into that diversification strategy, particularly given the growth potential of the temporary events structures market in the Middle East," they note.

----------

Reabold Resources PLC, up 19% at 0.1845p, 12-month range 0.15p-0.87p. Notes that Corallian Energy Ltd, in which it holds just under a 50% stake, has decided to undertake review of strategic options to maximise shareholder value. This will include fielding potential takeover offers for up to 100% of the firm. "Reabold remains supportive of Corallian, its board, and the timing of this strategic review. Reabold believes Corallian's flagship Victory gas development presents a compelling investment opportunity to any prospective investor," Reabold says.

----------

Real Good Food PLC, up 15% at 2.47p, 12-month range 1.42p-4.94p. The food manufacturer says revenue in six months to September 30 up 31% on a year ago and 0.7% above two years ago. Registers underlying earnings before interest, tax, depreciation and amortisation of GBP500,000 in period versus loss of GBP1.4 million a year ago. "We have made a good start to the year and the Group is well positioned for the seasonally busier second half of the year," says Executive Chair Mike Holt.

----------

Synairgen PLC, up 13% at 165.55p, 12-month range 74.8p-199.96p. The drug discovery and biotechnology company is informed that the external data safety monitoring board of the ACTIV-2 study has recommended that SNG001 advance into phase 3 in mild to moderate Covid-19 patients. "The advancement of SNG001 from phase 2 to phase 3 of the large ACTIV-2 trial is very welcome news and continues to build the case that our formulation of inhaled IFN-beta may have an important role in combatting CovidD-19 and future emerging virus threats," says Chief Executive Richard Marsden.

----------

AIM - LOSERS

----------

Accrol Group Holdings PLC, down 17% at 37.3p, 12-month range 33.50p-75.1p. The tissue converter notes "considerable" pressure on supply chains and higher costs, as well as shortage of HGV drivers restricting revenue growth. Says cost increases being successfully passed on, but there will be a time lag in passing on the full impact, resulting in earnings for financial year ending April 30 being "lower than previously expected".

----------

UK Oil & Gas PLC, down 7.5% at 0.1295p, 12-month range 0.1p-0.48p. Is "disappointed" by Isle of Wight Council's Planning Committee decision to refuse consent for the appraisal and testing of the Arreton oil and gas discovery. "Today's decision goes against last week's recommendation by the council's planning officers to approve the project. The company will now consider its position and whether to lodge an appeal with the Planning Inspectorate," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
25 Jan 2021 19:18

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

TRADING UPDATES: Intuitive Plots GBP250,000 Investment In Microsaic

Read more
20 Jan 2021 21:16

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

Read more
13 Jan 2021 10:24

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

Read more
11 Jan 2021 20:54

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 11:06

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Read more
18 Dec 2020 10:29

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

Read more
18 Nov 2020 13:59

finnCap Interim Profit More Than Doubles; Chair To Step Down

finnCap Interim Profit More Than Doubles; Chair To Step Down

Read more
13 Nov 2020 14:28

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

Read more
13 Nov 2020 10:24

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Read more
2 Nov 2020 20:03

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Read more
15 Oct 2020 11:39

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Read more
14 Oct 2020 18:02

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

Read more
29 Sep 2020 12:14

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Read more
9 Sep 2020 16:04

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.